Do any long term holders intend to subscribe for part or all of their entitlement in this CR? I've warmed to it. I still think the product works (so does the EMA - we "just" got the process wrong), we will miss out on first mover advantage - but it's a huge market we are pitching at. My guess is that once through phase 2 there will be many interested parties vying to assist with phase 3 - maybe a straight-out acquisition. IE this may be the last CR.
PS Anyone know what happened to the pain relief afforded to recruits in the previous trials - are there plans to monitor it in the coming trials?
My opinions only - have not spoken with management for many months. Neither am I a biochemist dyor.
TIS Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
